文献速递甲状腺疾病糖尿病

司美格鲁肽通过GLP-1R/PPARG/ACSL1通路重编程巨噬细胞抑制甲状腺乳头状癌生长

Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究在甲状腺乳头状癌(PTC)异种移植小鼠模型、人THP-1巨噬细胞与PTC细胞共培养体系及原代小鼠腹腔巨噬细胞中评估司美格鲁肽对肿瘤相关巨噬细胞(TAM)的调控。结果显示司美格鲁肽不显著影响PTC细胞增殖,但缩小肿瘤体积并抑制共培养体系中PTC细胞增殖,同时增加M1型、减少M2型巨噬细胞。机制上司美格鲁肽通过GLP-1R/PPARG/ACSL1通路调控巨噬细胞脂质代谢,促进TAM向M1表型转化并增强抗肿瘤活性。

要点

  • 司美格鲁肽不显著影响PTC细胞增殖,但缩小PTC异种移植小鼠肿瘤体积。
  • 司美格鲁肽增加M1型、减少M2型巨噬细胞,促进TAM向M1表型转化。
  • 机制涉及GLP-1R/PPARG/ACSL1通路调控巨噬细胞脂质代谢。

核心结论

  • 司美格鲁肽通过GLP-1R/PPARG/ACSL1信号通路调控巨噬细胞脂质代谢,促进TAM向M1表型转化并增强其抗肿瘤活性。
  • 这些发现提示司美格鲁肽可能改善治疗策略、减少不必要的甲状腺结节筛查并拓宽其临床应用。

研究设计与样本

  • 研究在甲状腺乳头状癌(PTC)异种移植小鼠模型、人THP-1巨噬细胞与PTC细胞共培养体系及原代小鼠腹腔巨噬细胞中给予司美格鲁肽。
  • 评估指标包括肿瘤大小、M1/M2巨噬细胞比例、PTC细胞增殖及极化标志物表达。

主要发现

  • 司美格鲁肽不显著影响PTC细胞增殖,但缩小肿瘤体积并抑制共培养体系中PTC细胞增殖。
  • 司美格鲁肽增加M1型巨噬细胞、减少M2型巨噬细胞,通过下调PPARG表达重编程极化。
  • 共培养体系中司美格鲁肽与PPARG激动剂共处理证实下游基因RSAD2、ACSL1和PLA2G7上调。
  • 沉默ACSL1抑制THP-1细胞脂质积累并促进向M2巨噬细胞表型极化。

临床怎么用

  • 原文结论认为司美格鲁肽可能改善治疗策略、减少不必要的甲状腺结节筛查并拓宽其临床应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The use of glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide, a novel class of antidiabetic medications, has raised concerns about potential adverse effects, particularly a possible association with thyroid cancer (TC). OBJECTIVE: This study aims to evaluate whether semaglutide influences the progression of TC by modulating tumor-associated macrophages (TAMs). METHODS: Semaglutide was administered to human papillary thyroid carcinoma (PTC) xenograft mouse models, coculture systems consisting of human THP-1 macrophage cells and PTC cells, and primary murine peritoneal macrophages. Assessments included tumor size, M1/M2 macrophage ratio, PTC cell proliferation, and polarization marker expression. RESULTS: Semaglutide did not significantly impact the proliferation of PTC cells but reduced tumor size and inhibited the proliferation of PTC cells in coculture systems. It increased M1 and decreased M2 macrophages, reprogramming polarization by downregulating PPARG expression. Cotreatment with semaglutide and a PPARG agonist in the coculture system confirmed the upregulation of downstream genes RSAD2, ACSL1, and PLA2G7. Silencing ACSL1 inhibited lipid accumulation in THP-1 cells and promoted polarization toward the M2 macrophage phenotype. CONCLUSION: Semaglutide modulates macrophage lipid metabolism through the GLP-1R/PPARG/ACSL1 signaling pathway. This modulation promotes the conversion of TAMs to the M1 macrophage phenotype, enhancing their anticancer activity. These findings suggest that semaglutide may improve therapeutic strategies, reduce unnecessary thyroid nodule screenings, and broaden its clinical applications.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang L, Zhang L, Ma R, et al. Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth. J Clin Endocrinol Metab. 2025. PMID: 39908200. doi:10.1210/clinem/dgaf053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。